Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review

References

• Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health 2013;16:686-95
   PubMed Web of Science ®Google Scholar
• The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Comparison of Submission Guidelines for selected countries on selected key features. Available by selecting all countries, submission guidelines, and preferred method to derive utility at Comparative table (compare selected countries on selected key features). 2015. http://www.ispor.org/PEguidelines/COMP3.asp. Accessed May 11, 2015
   Google Scholar
• The Brazier document states that it should be referenced as "Brazier, J.E., Longworth, L. NICE DSU Technical Support Document 8: An introduction to the measurement and valuation of health for NICE submissions. 2011. Available from http://www.nicedsu.org.uk. Accessed May 11, 2015
   Google Scholar
• SMC Secretariat. Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). Glasgow: Scottish Medicines Consortium, 2013. https://www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed May 11, 2015
   Google Scholar
• Blinman P, King M, Norman R, et al. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol 2012;23:1104-10
   PubMed Web of Science ®Google Scholar
• Kontodimopoulos N, Aletras VH, Paliouras D, et al. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009;12:1151-7
   PubMed Web of Science ®Google Scholar
• Roila F, Cortesi E. Quality of life as a primary end point in oncology. Ann Oncol 2001;12(3 Suppl):S3-6
   Google Scholar
• Davis S, Tappenden P, Cantrell A. A review of studies examining the relationship between progression-free survival and overall survival in advanced or metastatic cancer: report by the Decison Support Unit. 2012. http://www.nicedsu.org.uk/PFSOS%20Report.FINAL.06.08.12.pdf. Accessed January 23, 2014
   Google Scholar
• Stomach cancer: estimated incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer: GLOBOCAN, 2012. selecting “stomach cancer” at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed May 11, 2015
   Google Scholar
• Bendall J. Local palliation for advanced gastric cancer. 2013. http://www.uptodate.com/contents/local-palliation-for-advanced-gastric-cancer. Accessed January 6, 2014
   Google Scholar
• Oesophageal cancer: estimated incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer: GLOBOCAN, 2012. selecting “oesophageal cancer” at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed May 11, 2015
   Google Scholar
• Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013;23:3–9
   PubMed Web of Science ®Google Scholar
• International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM); 2014 update. Geneva: World Health Organisation, http://www.cdc.gov/nchs/icd/icd10cm.htm#icd2014. Accessed February 20, 2014
   Google Scholar
• Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: East vs. West. J Gastric Cancer 2012;12:55-62
   PubMedGoogle Scholar
• Petrelli F, Zaniboni A, Coinu A, et al. Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis. PloS One 2013;8:e83022
   PubMed Web of Science ®Google Scholar
• Stahl M, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(6 Suppl):vi51-6
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Gastric Cancer. National Comprehensive Cancer Network (NCCN), 2013. http://www.debbiesdream.org/portal/documents/33005/671772/2015+NCCN+Gastric+Cancer+Guidelines. Accessed May 11, 2015
   Google Scholar
• Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-74
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Esophageal and Esophagogastric Junction Cancers. National Comprehensive Cancer Network (NCCN), 2015. http://www.debbiesdream.org/portal/documents/33005/671772/2015+NCCN+Esophageal+and+GE+Junction+Cancer+Guidelines. Accessed May 11, 2015
   Google Scholar
• Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer: is there enough evidence to call second-line therapy standard? World J Gastroenterol 2012;18:6376-8
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an International, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al; and the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535
   PubMed Web of Science ®Google Scholar
• Papaioannou D, Brazier JE, Paisley S. NICE DSU Technical Support Document 9: the identification, review and synthesis of health state utility values from the literature. UK: School of Health and Related Research, University of Sheffield, 2010. http://www.nicedsu.org.uk/TSD9%20HSUV%20values_FINAL.pdf. Accessed May 11, 2015
   Google Scholar
• Aultman R, Urspruch A. Analysis of the EQ-5D questionnaire for patients with advanced HER2-positive gastric cancer based on the ToGA study. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November 2010; PCN116
   Google Scholar
• Curran D, Pozzo C, Zaluski J, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res 2009;18:853-61
   PubMed Web of Science ®Google Scholar
• Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma – a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004;40:1862-71
   PubMed Web of Science ®Google Scholar
• McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495-500
   PubMed Web of Science ®Google Scholar
• McNamee P, Glendinning S, Shenfine J, et al. Chained time trade-off and standard gamble methods. Applications in oesophageal cancer. Eur J Health Econ 2004;5:81-6
   PubMedGoogle Scholar
• O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998;32:76-80
   PubMed Web of Science ®Google Scholar
• Wildi SM, Cox MH, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004;99:1044-9
   PubMed Web of Science ®Google Scholar
• CRD and CHE Technology Assessment Group. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. York: University of York, CRD, 2010
   Google Scholar
• CRD and CHE Technology Assessment Group. Capecitabine for the treatment of advanced gastric cancer: a single technology appraisal. York: University of York, CRD, 2010
   Google Scholar
• Medical Services Advisory Committee. Public Summary Document: Application No. 1163 - Assessment of HER2 gene amplification for use of trastuzumab in gastric cancer. Australian Government medical Services Advisory Committee, 2012. http://www.msac.gov.au/internet/msac/publishing.nsf/content/1CF9BC42028CF922CA257880001EB9DF/$File/1163%20-%20PSD-HER2geneamplificationforuseoftrastuzumabingastriccancer%20(D13-1647473).pdf. Accessed May 11, 2015
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450-7
   PubMed Web of Science ®Google Scholar
• Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15:1773-81
   PubMed Web of Science ®Google Scholar
• Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Australian Government: Department of Health and Ageing, 2008. http://www.ispor.org/peguidelines/source/Australia-Guidelines-for-preparing-submissions-to-the-Pharmaceutical-Benefits-Advisory-Committee-2008.pdf. Accessed May 11, 2015
   Google Scholar
• Hisashige A, Sasako M, Nakajima T. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer 2013;13:443
   PubMed Web of Science ®Google Scholar
• Avery KNL, Metcalfe C, Barham CP, et al. Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surgery 2007;94:1369-76
   PubMed Web of Science ®Google Scholar
• Bonnetain F, Bouche O, Conroy T, et al. Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. Gastroenterol Clin Biol 2005;29:1113-24
   PubMed Web of Science ®Google Scholar
• Chung HC, Bang Y, Van Cutsem E, Kang Y, Hamamoto Y, Moiseyenko V, et al. (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. J Clin Oncol 2010;28:15s (suppl; abstr 4048)
   Google Scholar
• Huang CC, Lien HH, Wang PC, et al. Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures. Dig Surg 2007;24:59-65
   PubMed Web of Science ®Google Scholar
• Jakstaite G, Samalavicius NE, Smailyte G, Lunevicius R. The quality of life after a total gastrectomy with extended lymphadenectomy and omega type oesophagojejunostomy for gastric adenocarcinoma without distant metastases. BMC Surg 2012;12:11
   PubMed Web of Science ®Google Scholar
• Liu J, Yang K, Chen XZ, et al. Quality of life following laparoscopic-assisted distal gastrectomy for gastric cancer. Hepatogastroenterology 2012;59:2207-12
   PubMed Web of Science ®Google Scholar
• Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss group for clinical cancer research. J Clin Oncol 2007;25:3217-23
   PubMed Web of Science ®Google Scholar
• Rutegard M, Lagergren J, Rouvelas I, et al. Population-based study of surgical factors in relation to health-related quality of life after oesophageal cancer resection. Br J Surg 2008;95:592-601
   PubMed Web of Science ®Google Scholar
• Centre for Reviews Dissemination. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens (Structured abstract). NHS Econ Eval Database 2013; (3). Available online: http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&ID=21995001246. Accessed August 13, 2015
   Google Scholar
• Centre for Reviews Dissemination. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer (Structured abstract). NHS Econ Eval Database 2013; (3). Available online: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=21995000685. Accessed August 13, 2015
   Google Scholar